基本信息
唐士兵  男  博导  中国科学院广州生物医药与健康研究院
电子邮件: tang_shibing@gibh.ac.cn
通信地址: 广州市开源大道190号
邮政编码:

研究领域

​运用药物化学和化学生物学等学科的技术手段发现活性分子并将其应用于化学生物学基础研究和创新药物开发,特别是针对肿瘤和代谢性疾病等疾病的新型靶点进行新分子实体发现和临床前研究。

研究方向主要为:1)恶性肿瘤、代谢性疾病等疾病的药物研发;2)生物活性工具分子的设计合成和应用研究;3)小分子药物的合成策略和工艺优化。


招生信息

招生专业
100701-药物化学
0703Z1-化学生物学
070303-有机化学
招生方向
新药设计与发现
活性工具分子设计与应用
小分子药物合成策略和工艺优化

教育背景

2006-09--2011-06   兰州大学   博士
2002-09--2006-06   吉林大学   学士
学位

2002-2006

本科   专业:化学       吉林大学化学学院 

导师:母瀛 教授

2006-2011

 

博士   专业:有机化学   兰州大学化学化工学院,功能有机分子国家重点实验室

导师:厍学功 教授


工作经历

2011-2017

博士后,美国加州大学旧金山分校格拉斯通研究所 (Gladstone Institutes, UCSF, USA),导师:丁胜 教授

2017-至今

课题组长、研究员,中国科学院广州生物医药与健康研究院


工作简历
2017-08~现在, 中国科学院广州生物医药与健康研究院, 研究员
2011-07~2017-07,美国加州大学旧金山分校, 博士后
社会兼职
2023-06-01-今,广东省研究型医院学会, 理事

教授课程

化学生物学

专利与奖励

4. 一种小分子化学交联剂及其制备方法和应用,申请号:202310163905X,申请日:2023年02月24日,发明人:唐士兵;杨兵; 吴婷,申请国家:中国。

3. DNMT1 inhibitors, pharmaceutical compositions, and therapeutic applications,申请号:PCT/CN2023/073678,申请日:2023年01月29日,发明人:Tang, Shibing; Kong, Xiangqian; Luo, Cheng; Zhao, Kehao; Li, Zhihai,申请国家: PCT申请,待进入具体国家。

2. 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物,申请号:PCT/CN2020/094580,授权专利号:202080018398.5,授权公告日:2022年05月10日,发明人:唐士兵; 曾少高; 米琦.丹尼尔.托特雷拉,申请及授权国家:PCT进入中国并获授权。

1. Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease,申请号:PCT/US2018/046272 (WO2019032999),申请日:2018年08月10日,发明人:Reh, Thomas A.; Nakamura, Paul; Shimchuk, Andy; Tang, Shibing; Ding, Sheng,申请国家:PCT申请,已进入美国、日本、中国、欧盟、加拿大、澳大利亚等国家审查阶段。


出版信息

24. Wu T#, Li ST#, Ran Y#, Lin Y, Liu L, Zhang X, Zhou L, Zhang L, Wu D, Yang B*, Tang S*. Mapping protein direct interactome of oxidoreductases with small molecular chemical cross-linkers in live cells. Redox Biol. 2023 May;61:102642.

23. Shi R, Shi X, Qin D, Tang S, Vermeulen M, Zhang X. SNX27-driven membrane localisation of OTULIN antagonises linear ubiquitination and NF-κB signalling activation. Cell Biosci. 2021 Jul 27;11(1):146. PMID: 34315543

22. Liu X, Zhang Y, Chu Y, Zhao X, Mao L, Zhao S, Lin S, Hui X, Gu P, Xu Y, Loomes K, Tang S*, Nie T*, Wu D*. The natural compound rutaecarpine promotes white adipocyte browning through activation of the AMPK-PRDM16 axis. Biochem Biophys Res Commun. 2021;545:189-194. PMID: 33561654 

21. Tan J, Liu H, Huang M, Li N, Tang S, Meng J, Tang S, Zhou H, Kijlstra A, Yang P, Hou S. Small molecules targeting RORγt inhibit autoimmune disease by suppressing Th17 cell differentiation. Cell Death Dis. 2020 Aug 22;11(8):697. PMID: 32829384 

20. Zhao S, Chu Y, Zhang Y, Zhou Y, Jiang Z, Wang Z, Mao L, Li K, Sun W, Li P, Jia S, Wang C, Xu A, Loomes K, Tang S, Wu D, Hui X, Nie T.Linifanib exerts dual anti-obesity effect by regulating adipocyte browning and formation. Life Sci. 2019 Apr 1;222:117-124. PMID: 30708100 

19. Sun W, Zhao X, Wang Z, Chu Y, Mao L, Lin S, Gao X, Song Y, Hui X, Jia S, Tang S, Xu Y, Xu A, Loomes K, Wang C, Wu D, Nie T. Tbx15 is required for adipocyte browning induced by adrenergic signaling pathway. Mol Metab. 2019 Oct;28:48-57. PMID: 31352005

18. Hou L#, Yang G#, Tang S#, Alcazar C, Joshi P, Strassberg Z, Kim M, Kawamura M, Woo YJ, Shrager J, Ding S, Huang NF. A small molecule derived from carboxyethylpyrrole protein adducts promotes angiogenesis in a mouse model of peripheral arterial disease. J Am Heart Assoc. 2018 Sep 18;7(18):e009234. PMID: 30371212 (#equal contribution)

17. Qin Y#, Tang S#, Zhen G, Ding Q, Ding S, Cao X. Bone-targeted delivery of TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati-Engelmann disease. Ann N Y Acad Sci. 2018 Dec; 1433(1):29-40. PMID: 30091466 (#equal contribution)

16. Yang B#, Tang S#, Ma C#, Li ST, Shang GC, Dang B, DeGrado WF, Dong MQ, Wang PG, Ding S, Wang L. Spontaneous and specific chemical cross-linking in live cells to capture and identify protein interactions. Nat Commun. 2017 Dec 21;8(1):2240. PMID: 29269770 (#equal contribution)

15. Xie M#, Tang S#, Li K, Ding S. Pharmacological reprogramming of somatic cells for regenerative medicine. Acc Chem Res. 2017 May 16; 50(5):1202-1211. PMID: 28453285. (#equal contribution)

14. Mohamed TMA, Stone NR, Berry EC, Radzinsky E, Huang Y, Pratt K, Ang Y, Yu P, Wang H, Tang S, Magnitsky S, Ding S, Ivey KN, Srivastava D. Chemical enhancement of in vitro and in vivo direct cardiac reprogramming. Circulation. 2017 Mar 7; 135(10):978-995. PMID: 27834668. (a number of major media reports, including ABC 7, Fierce Biotech, Daily Mail, etc.)

13. Nie B, Nie T, Hui X, Gu P, Mao L, Li K, Yuan R, Zheng J, Wang H, Li K, Tang S, Zhang Y, Xu T, Xu A, Wu D, Ding S. Brown adipogenic reprogramming induced by a small molecule. Cell Rep. 2017 Jan 17;18(3):624-635. PMID: 28099842. 

12. Nakamura PA, Shimchuk AA, Tang S, Wang Z, Degolier K, Ding S, Reh TA. Small molecule Photoregulin3 prevents retinal degeneration in the RhoP23H mouse model of Retinitis Pigmentosa. eLife 2017 Nov 17; 6. pii: e30577. PMID: 29148976. 

11. Nakamura PA, Tang S, Shimchuk AA, Ding S, Reh TA. Potential of small molecule-mediated reprogramming of rod photoreceptors to treat retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2016 Nov 1; 57(14):6407-6415. PMID: 27893103. (reported by Foundation Fighting Blindness)

10. Tang S#, Xie M#, Cao N, Ding S. Patient-specific induced pluripotent stem cells for disease modeling and phenotypic drug discovery. J Med Chem. 2016 Jan 14; 59(1):2-15. PMID: 26322868. (#equal contribution)

9. Zhu S, Russ HA, Wang X, Zhang M, Ma T, Xu T, Tang S, Hebrok M, Ding S. Human pancreatic beta-like cells converted from fibroblasts. Nat Commun. 2016 Jan 6; 7:10080. PMID: 26733021. (a number of major media reports, including Fox News, The Independent, SF Business Times, etc.)

8. Yu C#, Liu K#, Tang S#, Ding S. Chemical approaches to cell reprogramming. Curr Opin Genet Dev. 2014 Oct; 28:50-6. PMID: 25461450. (#equal contribution)

7. Dai Q, Xie X, Xu S, Ma D, Tang S, She X. Total syntheses of Tardioxopiperazine A, Isoechinulin A, and Variecolorin C. Org Lett. 2011 May 6; 13(9):2302-5. PMID: 21456528. 

6. Tang S, Xie X, Wang X, He L, Xu K, She X. Concise total syntheses of (+)-strictifolione and (6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-enyl]-5,6-dihydro-2H-pyran-2-one. J Org Chem. 2010 Dec 3; 75(23):8234-40. PMID: 21067232.

5. Sun Y, Yu B, Wang X, Tang S, She X, Pan X. Stereoselective syntheses of four diastereomers of 3,9,12-trihydroxycalamenene via a benzobicyclo[3.3.1] intermediate. J Org Chem. 2010 Jun 18; 75(12):4224-9. PMID: 20481593. 

4. Wang W, Zhang J, He J, Tang S, Wang X, She X, Pan X. Asymmetric total synthesis of (-)-Cladospolide B. Chin J Chem. 2008, 26(6), 1109-1113. 

3. Tang S, He J, Sun Y, He L, She X. Efficient and regioselective synthesis of 5-hydroxy-2-isoxazolines: versatile synthons for isoxazoles, beta-lactams, and gamma-amino alcohols. J Org Chem. 2010 Mar 19; 75(6):1961-6. PMID: 20151710. 

2. He J, Tang S, Tang S, Liu J, Sun Y, Pan X, She X. Assembly of functionalized α-hydroxy carbonyl compounds via combination of N-heterocyclic carbene and Pd catalysts. Tetrahedron Lett. 2009, 50 (4), 430-433.

1. Tang S, He J, Sun Y, He L, She X. Efficient and regioselective one-pot synthesis of 3-substituted and 3,5-disubstituted isoxazoles. Org Lett. 2009 Sep 3; 11(17):3982-5. PMID: 19708706. (highlighted by scientific journal SynFacts)


科研活动

   
科研项目
( 1 ) 选择性抑制STAT3通路促进白色脂肪细胞褐色化的抗肥胖症候选药物发现及调控机制研究, 负责人, 国家任务, 2019-01--2022-12
( 2 ) 代谢性疾病个性化药物研究, 参与, 中国科学院计划, 2018-01--2019-12
( 3 ) 基于基因回路调控胰岛细胞分化的研究, 参与, 国家任务, 2020-01--2024-12
( 4 ) 基于全新作用机制的DNA甲基化抑制剂发现和抗实体瘤研究, 参与, 其他国际合作项目, 2022-01--2024-12

合作情况

   
项目协作单位